Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Glaukos Corporation
Study ID
NCT06057051
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • iStent Infinite — DEVICE
    iStent Infinite Trabecular Micro-Bypass System

Study Details

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment

Key Dates

Start date
Sep 1, 2023
Status verified
Sep 2023
Primary completion
Aug 31, 2025
Completion
Aug 31, 2027

Study Design

Enrollment
245 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: iStent Infinite
    iStent Infinite Trabecular Micro-Bypass System

Primary Outcome Measure

Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline [ Time Frame: 12 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Glaukos Investigator SiteCincinnatiOhio45242
Dari Parizadeh

Find similar trials in Cincinnati, OH

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Glaukos Investigator Site· Cincinnati, OH

Related Studies